Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04401059
Other study ID # HangzhouNU-2
Secondary ID
Status Recruiting
Phase Phase 4
First received
Last updated
Start date November 9, 2020
Est. completion date March 30, 2026

Study information

Verified date December 2023
Source Hangzhou Normal University
Contact Tian Xie, PhD
Phone +86-13606707928
Email xbs@dljg.sina.net
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a nationwide, multicenter and prospective cohort study. The purpose of this study is to evaluate the synergistic effect and safety of Elemene plus TKIs in EGFR-mutated advanced non-small cell lung cancer.


Description:

About 9.2%-45.8% of Chinese patients with Non-small cell lung cancer were positive for EGFR gene mutation. Gefitinib, Erlotinib, Icotinib, Afatinib showed efficacy superior to that of chemotherapy in the treatment of EGFR mutation positive advanced NSCLC, and lower rates of serious adverse events. However, after a median of 8 to 13 months of disease control, patients ultimately progress due to acquired resistance of EGFR-TKIs. Elemene, a chemotherapeutic isolated from the Chinese medicinal herb Rhizoma Zedoariae, has been shown to have a comprehensive anti-tumor effect and the potential effect on reversing drug resistance. In this study, about 22 research centers will participate in. We planned to enroll 744 patients with advanced non-small cell lung adenocarcinoma who were positive for EGFR mutations. The dynamic random method will be adopted in this study. Patients will be randomly divided into the experimental group(Elemene plus first or third generation EGFR-TKIs), and control group (First or third generation EGFR-TKIs, only). The purpose of this study is evaluating the synergistic effect and safety of Elemene plus TKIs in EGFR-mutated advanced non-small cell lung cancer. We also try to analyze the correlation between molecular biomarkers and patient prognosis, including but not limited to drug-resistant genes and circulating tumor cells.


Recruitment information / eligibility

Status Recruiting
Enrollment 744
Est. completion date March 30, 2026
Est. primary completion date September 30, 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Age = 18. 2. Histologically or cytologically confirmed advanced non-small cell lung adenocarcinoma(stage IIIB~IV). 3. Patients with EGFR mutations (deletions in exon 19 and L858R in exon 21 of the EGFR gene), plan to receive First-generation EGFR-TKIs (Gefitinib, Erlotinib, Icotinib) or third generation EGFR-TKIs (including but not limited to Osimertinib, Almonertinib, Furmonertinib) monotherapy for the first time (patients who have been using first- or third-generation EGFR-TKIs for less than 28 days can be enrolled). 4. Patients positive for EGFR gene mutation (deletions in exon 19 and L858R in exon 21 of the EGFR gene), with disease progression after receiving chemotherapy can be enrolled. 5. Confirmed by investigators, tumor tissue can't be surgically excised. 6. No prior exposure to elemene injectable and/or oral emulsion within one month. 7. Prior exposure to other Chinese patent medicine with similar efficacy within one month. If more than one month, patients can be enrolled after a 30-day washout period (without continuing to use the above medications). 8. The participant must be capable of understanding and complying with the protocol and willing to sign a written informed consent document. Exclusion Criteria: 1. Patients with any EGFR mutations other than 19DEL or 21L858R. 2. Accompanied by other active tumors. (Except for stable basal cell carcinoma after treatment, If metachronous tumors have been controlled, participating was allowed ) 3. Exposure to First- or third-generation EGFR-TKIs combined treatment, for example, chemotherapy, anti-angiogenesis therapy. 4. Receiving radiotherapy or chemotherapy. 5. Pregnant or lactating women. 6. Allergic to Elemene. 7. Participating in other drug clinical trials. 8. Refuse to comply with the follow-up. 9. The researchers did not consider it appropriate to participate in this study for other reasons.

Study Design


Intervention

Drug:
Elemene plus first or third generation EGFR-TKIs
Elemene Injectable Emulsion: 20ml: 88mg, 6 injections each time, once a day, continuous intravenous drip for 5 days. Continue to use Elemene Oral Emulsion. For specific usage, refer to the drug label. Elemene Oral Emulsion: 20ml: 176mg, 1 dose each time, 3 times a day. Use the Elemene Oral Emulsions until the disease progresses, the intolerable toxicity, the patient withdraws from the study, or dies for any reason. First or third generation EGFR-TKIs: refer to the drug label.
First or third generation EGFR-TKIs
refer to the drug label.

Locations

Country Name City State
China Peking University Cancer Hospital Beijing
China Sichuan Academy of Medical Sciences· Sichuan Province People's Hospital Chengdu Sichuan
China Hangzhou Cancer Hospital Hangzhou Zhejiang
China The Second People's Hospital of Yangcheng County Jincheng Shanxi
China Affiliated Hospital of Nantong University Nantong Jiangsu
China Panjin Central Hospital Panjin Liaoning
China Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine Shanghai Shanghai

Sponsors (2)

Lead Sponsor Collaborator
Tian Xie LinkDoc Technology (Beijing) Co. Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Other Quality of life (QOL) Quality of Life (QOL) was measured using the European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire (EORTC QLQ-C30 + LC 13). Start of treatment until 1-year follow-up
Other Karnofsky Performance Scale (KPS) KPS: Performance status were measured using Karnofsky Performance Scale (KPS) Start of treatment until 1-year follow-up
Other Traditional Chinese Medical(TCM) symptoms score TCM symptom score: Traditional Chinese Medical symptoms were measured from these eight aspects: chest pain, oppression in the chest, blood stasis, shortness of breath, weakness, palpitations, dry mouth, vexation. Particular attention should be paid to chest pain and weakness. Start of treatment until 1-year follow-up
Other Molecular biomarkers Including but not limited to drug-resistant genes and circulating tumor cells. Such as PD-L1?MSI-H/dMMR?TMB?HLA?POLE?POLD1?DDR?TP53?KRAS?BRCA2?PBRM1?MDM2/4?EGFR?ALK?PTEN?JAK1/2?DNMT3A?STK11. Start of treatment until 1-year follow-up
Primary PFS PFS was defined as the interval from the date of randomization to the date of the first evidence of disease progression or death, whichever occurs first. Disease progression was defined according to RECIST 1.1. Start of treatment until 1-year follow-up
Secondary ORR ORR was defined as the percentage of participants with the best overall response (BOR) of complete response (CR) or partial response (PR) based on RECIST 1.1. Start of treatment until 1-year follow-up
Secondary DCR Disease Control Rate (DCR) = Complete Response (CR) + Partial Response (PR) + Stable Disease (SD) as defined by RECIST 1.1. Start of treatment until 1-year follow-up
Secondary OS Overall survival (OS) was defined as the interval from the date of randomization to date of death from any cause, or the date of last known follow-up alive. Start of treatment until 1-year follow-up
Secondary Incidence and severity of AE or SAE Any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment.
A serious adverse event (experience) or reaction is any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, or is a congenital anomaly/birth defect
Start of treatment until 30 days after the last treatment
Secondary Incidence and severity of ADR or SADR All noxious and unintended responses to a medicinal product related to any dose should be considered adverse drug reactions.
A SADR is a serious ADR according to the above criteria of SAE.
Start of treatment until 30 days after the last treatment
See also
  Status Clinical Trial Phase
Recruiting NCT05283226 - Study to Evaluate the Safety and Efficacy of Oral NRC-2694-A in Combination With Paclitaxel in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma, Who Progressed on or After Immune Checkpoint Inhibitor Therapy Phase 2
Active, not recruiting NCT04362072 - Study of Lorlatinib In People With ALK-positive Non-small Cell Lung Cancer Phase 4
Completed NCT04033991 - Study of Patients With Metastatic and/or Advanced Renal Cell Carcinoma, Treated With Sunitinib/Axitinib.
Recruiting NCT02292641 - Beyond TME Origins N/A
Not yet recruiting NCT02907606 - Urinary Circulating Tumor DNA Detection in Non-small Cell Lung Cancer: a Prospective Study N/A
Completed NCT02507544 - A Safety and Pharmacokinetic Study of TRX-818 Administered Orally to Patients With Advanced Cancer Phase 1
Completed NCT01942200 - A Non Interventional Study With Oxaliplatin Onkovis (Oxaliplatin) Utilized for the Treatment of Cancer
Completed NCT01061645 - Study of MOC31-PE in Antigen Positive Carcinomas Phase 1
Terminated NCT00557596 - A Phase 1-2, XIAP Antisense AEG35156 With Gemcitabine in Patients With Advanced Pancreatic Cancer Phase 1/Phase 2
Completed NCT00532155 - A Study of Aflibercept Versus Placebo in Patients With Second-Line Docetaxel for Locally Advanced or Metastatic Non-Small-Cell Lung Cancer Phase 3
Completed NCT00216372 - Efficacy and Safety of Lanreotide Microparticles as Palliative Treatment in Peritoneal Carcinomatosis Phase 3
Recruiting NCT06022757 - Study of XNW5004 Tablet in Combination With KEYTRUDA® (Pembrolizumab) in Subjects With Advanced Solid Tumors Who Failed Standard Treatments (KEYNOTE F19) Phase 1/Phase 2
Recruiting NCT05520281 - Short-term Psychodynamic Psychotherapy in Serious Physical Illness N/A
Recruiting NCT05752357 - The Role of Pre-operative and Post-operative Circulating Tumor Cells in Gastric Cancer.
Not yet recruiting NCT05023928 - Tumor Antigen-sensitized DC Vaccine as an Adjuvant Therapy for Esophagus Cancer Phase 1
Completed NCT00446446 - PRISM (Panitumumab Regimen In Second-line Monotherapy of Head and Neck Cancer) Phase 2
Recruiting NCT04566952 - Anlotinib Combined With Dose-reduced Olaparib in Patients With Platinum-Sensitive Recurrent Ovarian Cancer Phase 2
Not yet recruiting NCT06112041 - The Prospective Clinical Study of Precision PRaG Therapy in Elderly Patients With Advanced Solid Malignant Tumors (PRaG9.0) Phase 2
Completed NCT03562897 - Evaluation of Ocoxin-Viusid® in Advanced or Metastatic Ovarian Epithelial Cancer Phase 2
Recruiting NCT06013111 - An Exploratory Clinical Study Evaluating the Safety and Efficacy of Anti-CEA-CAR-T Cells Injection in Patients With CEA+ Locally Advanced and/or Metastatic Solid Tumors Phase 1